The Alternatively Spliced Anti-Angiogenic Family of VEGF Isoforms VEGFxxxb in Human Kidney Development
- 27 November 2008
- journal article
- research article
- Published by S. Karger AG in Nephron Physiology
- Vol. 110 (4), p57-p67
- https://doi.org/10.1159/000177614
Abstract
Background/Aim: Vascular endothelial growth factor (VEGF), required for renal development, is generated by alternative splicing of 8 exons to produce two families, pro-angiogenic VEGFxxx, formed by proximal splicing in exon 8 (exon 8a), and anti-angiogenic VEGFxxxb, generated by distal splicing in exon 8 (exon 8b). VEGF165b, the first described exon 8b-containing isoform, antagonises VEGF165 and is anti-angiogenic in vivo. Methods: Using VEGFxxxb-specific antibodies, we investigated its expression quantitatively and qualitatively in developing kidney, and measured the effect of VEGF165b on renal endothelial and epithelial cells. Results: VEGFxxxb formed 45% of total VEGF protein in adult renal cortex, and VEGF165b does not increase glomerular endothelial cell permeability, it inhibits migration, and is cytoprotective for podocytes. During renal development, VEGFxxxb was expressed in the condensed vesicles of the metanephros, epithelial cells of the comma-shaped bodies, invading endothelial cells and epithelial cells of the S-shaped body, and in the immature podocytes. Expression reduced as the glomerulus matured. Conclusion: These results show that the anti-angiogenic VEGFxxxb isoforms are highly expressed in adult and developing renal cortex, and suggest that the VEGFxxxb family plays a role in glomerular maturation and podocyte protection by regulating the pro-angiogenic pro-permeability properties of VEGFxxx isoforms.Keywords
This publication has 43 references indexed in Scilit:
- Recombinant human VEGF165b protein is an effective anti-cancer agent in miceEuropean Journal of Cancer, 2008
- VEGF165b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapyBritish Journal of Cancer, 2008
- Impaired Glomerular Maturation and Lack of VEGF165b in Denys-Drash SyndromeJournal of the American Society of Nephrology, 2007
- The anti-angiogenic VEGF isoform VEGF165b transiently increases hydraulic conductivity, probably through VEGF receptor 1in vivoJournal Of Physiology-London, 2006
- Conditional and inducible transgene expression in mice through the combinatorial use of Cre-mediated recombination and tetracycline inductionNucleic Acids Research, 2005
- VEGF165b, an Inhibitory Vascular Endothelial Growth Factor Splice VariantCancer Research, 2004
- Differentiated human podocytes endogenously express an inhibitory isoform of vascular endothelial growth factor (VEGF165b) mRNA and proteinAmerican Journal of Physiology-Renal Physiology, 2004
- Transcriptional regulation of podocyte specification and differentiationMicroscopy Research and Technique, 2002
- Identification of a Natural Soluble Form of the Vascular Endothelial Growth Factor Receptor, FLT-1, and Its Heterodimerization with KDRBiochemical and Biophysical Research Communications, 1996
- Abnormal blood vessel development and lethality in embryos lacking a single VEGF alleleNature, 1996